JAJosé Tadeu Campos de Avelar

José Tadeu Campos de Avelar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


José Tadeu Campos de Avelar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of artificial intelligence on breast care pathways and future perspectives

    by Virgínia de Assis Silva, Renata Capanema Saliba Franco, Anna Dias Salvador, Waldeir José de Almeida, Gabriel Oliveira Bernardes Gil, Bernardo Bacelar de Faria, Jairo Luiz Coelho, José Tadeu Campos Avelar

    Artificial intelligence (AI) is a sophisticated technology already established in medicine. In mastology, there is robust evidence of the ability of AI software to optimize screening, reduce interval cancer rates, and decrease patient recall rates. In addition, AI provides parameters for predicting surgical complications and oncological therapeutic outcomes. Considering the rise of AI, this article aimed to conduct an integrative review, highlighting its main tools developed in mastology. A search was performed on the United States National Library of Medicine (PubMed) platform, using descriptors associated with AI and breast cancer. Retrospective studies, systematic reviews, and prospective clinical studies published in English in the last ten years were included. The results were organized by thematic areas and summarized in a table and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flowchart. Data analysis showed a concentration of information in the area of imaging — with advances in radiomics — and a still incipient, albeit promising, development in areas such as genetics and surgery. The article highlights the need for discussion on the ethical issues surrounding the implementation of AI. The reliability of data collection and manipulation must be guaranteed, and data automation should not imply automation of conduct, since medical responsibility in patient care is perennial.

  • Open Access

    Vacuum-assisted biopsy and excision of breast lesions: review and current indications

    by Letícia Martins de Araújo Campos Linhares, José Tadeu Campos de Avelar, Gabriela Ramos Alves, Thaís Paiva Moraes, Elizabeth Asuncion Sanchez de Ayub, Jairo Luis Coelho, Renata Capanema Saliba Franco

    Vacuum-assisted biopsy is an advance in breast diagnostics because it is a less invasive and more practical approach than conventional surgery, capable of diagnosing and treating certain lesions. Despite the still limited availability of the method, related to its cost and the number of professionals qualified to perform it, the potential of vacuum-assisted biopsy and excision in the practice of mastologists is unquestionable. The attending physician is expected to understand the methods, as well as the indications pertinent to them. Recognizing the impossibility of exhausting the subject, the objective of this study is to conduct a narrative review, summarizing the indications for vacuum-assisted breast biopsy and excision currently, according to the available scientific evidence.


  • Open Access

    Epidemiological and clinicopathological parameters related to the neoadjuvant chemotherapy for breast cancer during the COVID-19 crisis

    by Maria Fernanda da Motta Sperotto Valadares Gontijo, Letícia Martins de Araújo Campos Linhares, Luisa Lazarino de Souza Campos, Marcela de Oliveira Sá, Caroline Cançado Avelar, João Pedro Costa Apolinário, Paulo Henrique Costa Diniz, José Tadeu Campos de Avelar

    Introduction: Breast cancer, the second-leading cause of cancer-related deaths among women worldwide, is a complex and heterogeneous disease. Its socioeconomic aspects are recognized as determinants of clinical outcomes. The COVID-19 crisis negatively affected millions, particularly in impoverished macroregions like Brazil. Thus, influences on breast cancer patients’ journey may occur, particularly in the neoadjuvant settings, in which a coordinated and multidisciplinary approach is mandatory. The present study aimed to analyze the epidemiological and clinicopathological profile of breast cancer patients who underwent neoadjuvant chemotherapy during the pandemic in Brazil. Methods: This is a unicentric, retrospective, and descriptive cross-sectional study conducted by analyzing data obtained from electronic medical records of breast cancer patients who underwent neoadjuvant chemotherapy. Results: From March 2020 to December 2022, 55 patients underwent neoadjuvant chemotherapy. They presented an average age of 50.0 years (range 43.9–47.6). About 83.6% of the tumors were invasive ductal carcinomas, and the most prevalent molecular subtype was hormone receptor-positive. T2 tumors accounted for 50.9%, while compromised N1 axillary lymph nodes represented 52.7%. The most commonly used neoadjuvant chemotherapy combined anthracyclines, cyclophosphamide, and sequential taxane. Regarding postoperative pathological response, 42.2% showed a partial response after neoadjuvant treatment, and a complete pathological response of as high as 40.0% occurred. The luminal and hybrid luminal subtypes were those that achieved the greatest response to neoadjuvant therapy. The lack of pathological response was only found in the luminal molecular subtype. Conclusions: This study demonstrated the impacts of the COVID-19 pandemic on breast cancer patients’ journey. During this period of disruption in healthcare assistance, the disease presented at more advanced stages, but the pathologic complete response was higher than expected, and influences on chemotherapy decisions were not relevant. Overall, there were efforts to keep patients in the best breast cancer care.

  • Open Access

    Advances in breast imaging: a review on where we are and where we are going

    by Felipe Marcondes de Oliveira Coelho, Maria Fernanda Sperotto Valadares Gontijo, Katty Paulina Cabrera Loaiza, Renata Capanema Saliba Franco, José Tadeu Campos de Avelar

    Breast radiology has undergone significant advances in recent years, and, naturally, several possibilities open up for attending physicians. Concomitantly, it increases the responsibility to keep up to date and provide the best care for each patient. Aware of the complex implications that the implementation of some of the technological advances may bring, such as increased costs, limited availability of equipment, and a potential increase in examination time, the objective of this study is to carry out a narrative review and provide a collection of advances that, in our opinion, are already gaining ground and should be consolidated in clinical practice. We will discuss new breast imaging methods that can be used both for screening and for the diagnostic investigation of breast lesions and we will summarize the most relevant aspects of each of them, addressing the technique, applicability, positive aspects, and limitations of each modality in a standardized way.


  • Open Access

    The influence of germline mutations on breast cancer

    by Maria Fernanda Sperotto Valadares Gontijo, Luísa Lazarino, Caroline Avelar, João Pedro Apolinário, Henrique Galvão, Anna Dias Salvador, José Tadeu

    The ability to evade protection mechanisms and uncontrolled cell growth can lead to the development of mutations, whether somatic or germline, and consequently to the dreaded diagnosis of cancer. Breast cancer is considered the most common type of cancer in women in several regions of Brazil, mainly in the South and Southeast, second only to non-melanoma skin cancer. Approximately 5% to 10% of neoplasms are related to germline alterations that lead to hereditary predisposition. There is evidence of an association with mutations in nine genes, the highest risk being breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2). Due to its epidemiological importance, in this narrative review we observed the main genetic mutations and syndromes associated with breast carcinoma, the recommendations for screening in high-risk patients, and the indication for genetic counseling. Bibliographic research on the PubMed and Cochrane databases and analysis of the Guidelines Breast Cancer Risk Reduction and Breast Cancer Screening and Diagnosis, from June 2022 to September 2023. In this review, we observed a greater influence of germline mutations on breast cancer related to the genes BRCA1, BRCA2, PALB2, PTEN, CDH1, STK11 and, in Brazil, considered a country of ethnic-racial diversity, to TP53. As cancer screening in the country is opportunistic, knowledge of germline mutations associated with breast cancer offers specific screening recommendations for high-risk patients, indications for genetic counseling, and guidelines for prophylactic surgery, in addition to impacting the formulation of public screening policies.

  • Lifestyle and breast cancer: review article

    by Katty Paulina Cabrera Loaiza, Victoria Furquim Werneck Marinho, Thais Paiva Moraes, Renata Capanema Saliba Franco, Felipe Marcondes de Oliveira Coelho, Maria Fernanda Sperotto Valadares Gontijo, José Tadeu Avelar

    The aim of this study was to improve our knowledge about carcinogenesis and lifestyle, given their impact on the occurrence of breast cancer, emphasizing the importance of lifestyle changes as a preventive factor in the development of the disease. We conducted a bibliographic review with the analysis of 31 articles in English and Portuguese. As a result, the articles selected for study showed that factors such as diet, alcohol intake, smoking, obesity, physical activity, occupational exposure, hormonal factors (hormone therapy, contraceptives) and reproductive factors (menarche, menopause, nulliparity, pregnancy, breastfeeding) have a protective or risk effect on breast cancer. We conclude that eating healthy, with fruits, vegetables and greens, practicing moderate physical activity, avoiding alcoholic beverages and breastfeeding exclusively reduce the risk of developing breast cancer by 28%. Therefore, it is necessary to make the public aware of these modifiable risk factors.